BARCELONA, Spain, April 29, 2024 /PRNewswire/ -- MGI Tech (MGI), a company committed to building core tools and technology to lead life science, today introduced the latest addition to its range of sequencers, the portable and easy-to-use DNBSEQ-E25 platform, for the European and African market. In addition, the company showcased its current offering of laboratory automation and sequencing products, including the DNBSEQ-G99 and the entire workflow for the Million Microbiomes from Humans Project (MMHP), at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ESCMID Global also known as ECCMID 2024).

西班牙巴塞罗那，2024年4月29日/PRNewswire/--MGI Tech（MGI）是一家致力于构建核心工具和技术以引领生命科学的公司，今天为欧洲和非洲市场推出了其测序仪系列的最新产品，即便携式且易于使用的DNBSEQ-E25平台。此外，该公司在第34届欧洲临床微生物学和传染病大会（ESCMID Global也称为ECCMID 2024）上展示了其目前提供的实验室自动化和测序产品，包括DNBSEQ-G99和人类百万微生物组项目（MMHP）的整个工作流程。

During the event taking place from 27-30 April in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce its partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI's DNBSEQ™ platforms..

在4月27日至30日于巴塞罗那举行的活动中，MGI和ABL Diagnostics（Woippy，法国，泛欧交易所：ABLD–ISIN：FR001400AHX6）很高兴宣布其合作伙伴关系以及ABL Diagnostics的DeepChek®分析与MGI的DNBSEQ™平台的兼容性。。

Continue Reading

继续阅读

Dr. Yong Hou, General Manager of MGI Europe and Africa and Dr.Sofiane Mohamed, Head of Laboratory from ABL Diagnostics

MGI欧洲和非洲总经理Yong Hou博士和ABL Diagnostics实验室主任Sofiane Mohamed博士

'Once again, MGI showcases our commitment to supporting healthcare and scientific research and applications across Europe and Africa. We at MGI believe that the power and potential of genomics are boundless,' said Dr. Yong Hou, General Manager of MGI Europe and Africa. 'By providing our technology, expertise and technical facilities, we hope to enable more companies and institutions to develop content on our DNBSEQ platforms with greater ease, thereby empowering them in their work towards improving health and wellbeing for all.'.

“MGI再次展示了我们支持欧洲和非洲医疗保健、科学研究和应用的承诺。MGI欧洲和非洲总经理侯勇博士说，我们MGI相信基因组学的力量和潜力是无限的通过提供我们的技术、专业知识和技术设施，我们希望使更多的公司和机构能够更轻松地在我们的DNBSEQ平台上开发内容，从而使他们能够努力改善所有人的健康和福祉。”。

Introducing the portable DNBSEQ-E25 for European and African customers

为欧洲和非洲客户推出便携式DNBSEQ-E25

Answering the question 'What if your sequencing capabilities could be mobile?' MGI's flagship product under its E-series, DNBSEQ-E25 is a portable, user-friendly sequencer with a daily data throughput of up to 7.5 G. Built on the newly designed self-luminous biochemical system, the E25 has upgraded its sequencing system, flowcells, and sequencing cartridge, while featuring built-in bioinformatics.

回答“如果你的测序功能可以移动怎么办？”MGI的E系列旗舰产品DNBSEQ-E25是一款便携式，用户友好的测序仪，每日数据吞吐量高达7.5 G。E25基于新设计的自发光生化系统，升级了测序系统，流通池和测序盒，同时内置了生物信息学。

Its ease of setup means it is ready to run within minutes, and a quick turnaround time means it takes only 20 hours for PE150 from DNB to FASTQ data. DNBSEQ-E25 meets the application needs for infectious diseases, small genome sequencing, small panels and strand verification. The sequencer is now available for European and African customers.Empowering microbiology laboratories through collaboration with ABL DiagnosticsMoreover, at this year's ESCMID Global 2024, MGI announced a technical assessment of solutions by ABL Diagnostics (ABL), a Euronext-listed company that develops molecular biology assays and software for microbiology genotyping.

它易于安装意味着它可以在几分钟内运行，而快速的周转时间意味着PE150从DNB到FASTQ数据只需要20小时。DNBSEQ-E25满足传染病，小基因组测序，小面板和链验证的应用需求。测序仪现在可供欧洲和非洲客户使用。通过与ABL Diagnostics的合作增强微生物学实验室的能力此外，在今年的ESCMID Global 2024上，MGI宣布了ABL Diagnostics（ABL）对解决方案的技术评估，ABL Diagnostics是一家泛欧交易所上市公司，开发用于微生物学基因分型的分子生物学检测和软件。

The ABL DeepChek® assays have been successfully tested on MGI's DNBSEQ-G400 and DNBSEQ-G99 platforms. Further verification and validation studies of the DeepChek® assays will also be performed on the newly launched DNBSEQ-E25.'This new technical assessment with MGI will strengthen our presence in microbiology genotyping through the verification of our DeepChek® assays and software on additional Next Generation Sequencing (NGS) platforms,' said Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.

ABL DeepChek®分析已在MGI的DNBSEQ-G400和DNBSEQ-G99平台上成功测试。DeepChek®分析的进一步验证和验证研究也将在新推出的DNBSEQ-E25上进行。“与MGI进行的这项新技术评估将通过在其他下一代测序（NGS）平台上验证我们的DeepChek®分析和软件，加强我们在微生物学基因分型中的存在，”ABL Diagnostics诊断主管Dimitri Gonzalez说。

'It broadens the access to and offering of new types of NGS technology and end-to-end solutions for microbiology laboratories to cover a continuously growing infectious diseases applications portfolio, including but not limited to HIV, viral h.

“它扩大了微生物实验室获得和提供新型NGS技术和端到端解决方案的渠道，以涵盖不断增长的传染病应用组合，包括但不限于HIV，病毒h。